<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906798</url>
  </required_header>
  <id_info>
    <org_study_id>A88_10BE2109</org_study_id>
    <nct_id>NCT04906798</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 High-dose in Healthy Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in&#xD;
      Healthy Volunteers under Fasting Conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic&#xD;
      profiles and safety of CKD-385 high-dose in healthy volunteers under fasting conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 4, 2021</start_date>
  <completion_date type="Anticipated">July 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-385</measure>
    <time_frame>Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to time of CKD-385</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CKD-385</measure>
    <time_frame>Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the concentration-time curve from zero up to infinity of CKD-385</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CKD-385</measure>
    <time_frame>Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Time to maximum plasma concentration of CKD-385</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of CKD-385</measure>
    <time_frame>Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Terminal elimination half-life of CKD-385</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of CKD-385</measure>
    <time_frame>Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent clearance of CKD-385</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of CKD-385</measure>
    <time_frame>Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent Volume of Distribution of CKD-385</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Sequence1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Reference drug(D744)&#xD;
Period 2: Test drug(CKD-385)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test drug(CKD-385)&#xD;
Period 2: Reference drug(D744)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-385</intervention_name>
    <description>Test Drug</description>
    <arm_group_label>Sequence1</arm_group_label>
    <arm_group_label>Sequence2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D744</intervention_name>
    <description>Reference Drug</description>
    <arm_group_label>Sequence1</arm_group_label>
    <arm_group_label>Sequence2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults age≥19 years and age&lt;55 years at the time of screening&#xD;
&#xD;
          2. Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) &lt; 30.5kg/m2 and men's total body&#xD;
             weight ≥ 55 kg, women's total body weight ≥ 45 kg&#xD;
&#xD;
             * BMI = Weight(kg)/ Height(m)2&#xD;
&#xD;
          3. Individuals without congenital/chronic diseases and without abnormal symptoms or&#xD;
             diagnosis based on a medical examination within the last 3 years&#xD;
&#xD;
          4. Individuals who were deemed to be appropriate as study subjects following laboratory&#xD;
             tests (hematology, blood chemistry, urinalysis, viral/ bacterial, etc.) and vital&#xD;
             signs, ECG etc. performed at screening&#xD;
&#xD;
          5. Individuals who signed an informed consent form approved by the IRB of Chonbuk&#xD;
             National University Hospital and decided to participate in the study after being fully&#xD;
             informed of the study prior to participation, including the objective, content and&#xD;
             characteristics of the investigational product&#xD;
&#xD;
          6. Individuals who agreed proper contraception during the study and did consent to not&#xD;
             donation of sperm 1 month after the last dose of study drug infusion&#xD;
&#xD;
          7. Individuals with the ability and willingness to participate the entire study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject who has (or has histories of) clinically significant blood, kidney, endocrine,&#xD;
             respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or&#xD;
             allergic diseases(except for asymptomatic seasonal allergy at the time of&#xD;
             administration) or evidence(except for simple dental history such as dental calculus,&#xD;
             impacted tooth, wisdom tooth, etc.)&#xD;
&#xD;
          2. Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus&#xD;
             stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis&#xD;
             surgery or hernia surgery or tooth extraction surgery) that may affect the absorption&#xD;
             of drug&#xD;
&#xD;
          3. Subject who shows the following values as a result of laboratory tests&#xD;
&#xD;
             *ALT or AST &gt; 2 times upper limit of normal range&#xD;
&#xD;
          4. Subject who has a history of regular alcohol consumption in excess of 210 g/week&#xD;
             within 6 months of screening&#xD;
&#xD;
          5. Subject who smokes more than one pack of cigarette a day within 6 months of screening&#xD;
&#xD;
          6. Subject who took other clinical trial drugs or bioequivalence test drugs within 3&#xD;
             months before the first administration of clinical trial drug&#xD;
&#xD;
          7. Subject who conform to the specific items below&#xD;
&#xD;
               -  systolic blood pressure less than 90 mmHg, greater than 140 mmHg or diastolic&#xD;
                  blood pressure less than 60 mmHg or greater than 90 mmHg in a sitting position&#xD;
&#xD;
               -  Severe bradycardia (less than 50 beats/minute)&#xD;
&#xD;
          8. Subject who has significant alcohol abuse or drug abuse within a year of screening&#xD;
&#xD;
          9. Subject who took drugs which are known as disturbing drug metabolism within 30 days&#xD;
             prior to the first administration of clinical trial drug.&#xD;
&#xD;
         10. Subject who uses any of other drugs, including over-the-counter medications and&#xD;
             prescription medications within 10 days prior to first administration of clinical&#xD;
             trial drug.&#xD;
&#xD;
         11. Subject who donated whole blood within 2 months prior to first administration of&#xD;
             clinical trial drug or blood components within 1 month prior to first administration&#xD;
             of clinical trial drug&#xD;
&#xD;
         12. Subject who is hypersensitive to the components of a clinical trial drug or clinical&#xD;
             trial drug itself.&#xD;
&#xD;
         13. Subject had genetic dysfunctions like galactose intolerance, Lapp lactase deficiency&#xD;
             or glucose-galactose malabsorption&#xD;
&#xD;
         14. Subjects who were deemed inappropriate to participate in the study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Gul Kim, Professor</last_name>
    <phone>+82632593480</phone>
    <email>mgkim@jbcp.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Min-Gul Kim, Professor</last_name>
      <phone>+82632593480</phone>
      <email>mgkim@jbcp.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

